Brief: Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer
27/02/2026 15:32
Feb 27 (Reuters) - Astellas Pharma Inc 4503.T: PADCEV™ + KEYTRUDA® CUTS RISK OF RECURRENCE OR DEATH BY NEARLY 50% IN CISPLATIN-ELIGIBLE MUSCLE-INVASIVE BLADDER CANCER ASTELLAS- SAFETY PROFILE FOR PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB OBSERVED IN EV-304 CONSISTENT WITH PRIOR EXPERIENCE WITH COMBINATION Source text: ID:nBw7lsksZa Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)